B. Riley Securities Reiterates Buy on Actinium Pharma, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Yuan Zhi has reiterated a 'Buy' rating on Actinium Pharma (AMEX:ATNM) and maintained a $20 price target.
October 03, 2023 | 5:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B. Riley Securities has reiterated a 'Buy' rating on Actinium Pharma and maintained a $20 price target.
The reiteration of a 'Buy' rating by B. Riley Securities indicates a positive outlook for Actinium Pharma. The maintained price target of $20 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100